David R Snydman
Overview
Explore the profile of David R Snydman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
2940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Davis K, McDermott L, Snydman D, Aldridge B
Microbiol Spectr
. 2024 Jun;
12(8):e0097624.
PMID: 38916355
Methicillin-resistant (MRSA) bacteremia is a serious clinical challenge with high mortality rates. Antibiotic combination therapy is currently used in cases of persistent infection; however, the limited development of new antibiotics...
12.
Alsoubani M, Chow J, Rodday A, McDermott L, Walk S, Kent D, et al.
J Infect Dis
. 2024 May;
230(6):1501-1509.
PMID: 38779889
Background: The use of fidaxomicin is recommended as first-line therapy for all patients with Clostridioides difficile infection (CDI). However, real-world studies have shown conflicting evidence of superiority. Methods: We conducted...
13.
Alsoubani M, Chow J, Rodday A, Kent D, Snydman D
Open Forum Infect Dis
. 2024 Jan;
11(1):ofad622.
PMID: 38204563
Background: infection (CDI) is a leading cause of morbidity in immunocompromised hosts with increased risk of complications and recurrences. In this study, we examined the clinical effectiveness of fidaxomicin vs...
14.
Perry W, Chow J, Nelson J, Kent D, Snydman D
Transplant Direct
. 2023 Nov;
9(12):e1542.
PMID: 37928481
Background: Invasive infection remains a dangerous complication of heart transplantation (HT). No objectively defined set of clinical risk factors has been established to reliably predict infection in HT. The aim...
15.
Perry W, Martino A, Garcia M, Chow J, Snydman D
Transpl Immunol
. 2023 Mar;
78:101826.
PMID: 36934899
Background: Over a quarter of organ transplant recipients have low immunoglobulin levels in their early post-transplant course, which is associated with increased risk of infection and mortality. Although immunoglobulin level...
16.
Beaulac K, Fellman C, Wayne A, McDermott L, Snydman D, Doron S
Antimicrob Steward Healthc Epidemiol
. 2023 Jan;
3(1):e1.
PMID: 36714283
Transmission of bacteria between animals and humans in domestic households is increasingly recognized. We evaluated the presence of antimicrobial-resistant fecal bacteria in 8 dog-owner-dog pairs before and after the dog...
17.
Penney J, Rodday A, Sebastiani P, Snydman D, Doron S
Antimicrob Steward Healthc Epidemiol
. 2022 Dec;
2(1):e103.
PMID: 36483372
Objective: To evaluate the impact of the addition of an indication specification requirement to isolated urine-culture ordering on testing utilization. Design: Retrospective study utilizing interrupted time series analysis with negative...
18.
Perry W, Gardiner B, Price L, Rodriguez-Garcia M, Chow J, Snydman D
Transpl Infect Dis
. 2022 Oct;
24(6):e13960.
PMID: 36263467
Background: Limited data exist to describe sex-based differences in the severity of cytomegalovirus (CMV) infection after solid organ transplant (SOT). We sought to identify if a difference exists in likelihood...
19.
Penney J, Rodday A, Sebastiani P, Snydman D, Doron S
Infect Control Hosp Epidemiol
. 2022 Aug;
44(2):210-215.
PMID: 35924370
Objective: To evaluate the impact of changes to urinalysis with reflex to culture (UARC) reflex criteria on culture performance and clinical decision outcomes. Design: Retrospective study utilizing interrupted time series...
20.
Snydman D, McDermott L
Microbiol Spectr
. 2021 Dec;
9(3):e0190821.
PMID: 34908432
Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated activity against 341 recent clinical isolates. The addition of avibactam to aztreonam had no effect on the anaerobic activity...